Cogsmart Co., Ltd. announced that it has received ¥350 million in funding from Omron Ventures Co., Ltd., I'rom Group Co., Ltd., DG Daiwa Ventures Inc., IT-Farm Corporation, Makoto Capital Co., Ltd. and other investors
January 05, 2022
Share
Cogsmart Co., Ltd announced that it has raised ¥350 million in a round of funding on January 6, 2022. The transaction included participation from new investors Omron Ventures Co., Ltd., I'rom Group Co., Ltd., DG Daiwa Ventures Inc., IT-Farm Corporation, fund operated and involved by Makoto Capital Co., Ltd and individual investors. The company has raised ¥410 million in funding till date.
I'rom Group Co.,Ltd. is engaged in medical fields such as regenerative medicine and gene discovery. The Company operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The Company also provides business utilizing IT infrastructure.
Cogsmart Co., Ltd. announced that it has received ¥350 million in funding from Omron Ventures Co., Ltd., I'rom Group Co., Ltd., DG Daiwa Ventures Inc., IT-Farm Corporation, Makoto Capital Co., Ltd. and other investors
I'ROM GROUP CO., LTD. 
